Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Ups Negotiating Ante With Hostile Bid For Genentech

Executive Summary

By making a hostile bid for Genentech at a lower price, Roche is trying to address at least two important concerns in one blow: uncertainty over upcoming results of a key clinical trial for the blockbuster Avastin cancer medication and offsetting potentially higher financing costs needed to ink the deal due to the troubled economic climate

You may also be interested in...



ATLAS Phase III Data Point Avastin/Tarceva Combo In Positive Direction

Phase III results using an Avastin and Tarceva combination in non-small cell lung cancer could mean FDA will not insist on survival data before approving Tarceva's supplemental NDA in first-line maintenance non-small cell lung cancer. Genentech disclosed results from the ATLAS trial Feb. 2

ATLAS Phase III Data Point Avastin/Tarceva Combo In Positive Direction

Phase III results using an Avastin and Tarceva combination in non-small cell lung cancer could mean FDA will not insist on survival data before approving Tarceva's supplemental NDA in first-line maintenance non-small cell lung cancer. Genentech disclosed results from the ATLAS trial Feb. 2

Former FTC Economists Question TARP Funding Behind Pfizer-Wyeth Deal

In reviewing the proposed Pfizer-Wyeth merger, the Federal Trade Commission should take into account that the deal would indirectly be financed with government bail out money that banks could better spend elsewhere to stimulate the economy, two former FTC chief economists recommend

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel